[1]
|
Strader, D.B., Wright, T., Thomas, D.L. and Seeff, L.B. (2004) American Association for the Study of Liver Diseases. Diagnosis, Management, and Treatment of Hepatitis C. Hepatology, 39, 1147-1171. http://dx.doi.org/10.1002/hep.20119
|
[2]
|
Imazeki, F., Yokosuka, O., Fukai, K., et al. (2003) Favorable Prognosis of Chronic Hepatitis C after Interferon Therapy by Long-Term Cohort Study. Hepatology, 38, 493-502. http://dx.doi.org/10.1053/jhep.2003.50329
|
[3]
|
Chevaliez, S. and Pawlotsky, J.M. (2006) Hepatitis C Virus Serologic and Virologic Testes and Clinical Diagnosis of HCV-Related Liver Disease. International Journal of Medical Sciences, 3, 35-40. http://dx.doi.org/10.7150/ijms.3.35
|
[4]
|
National Institutes of Health Consensus Development Conference Statement (2002) Management of Hepatitis C. Hepatology, 36, S3-S20.
|
[5]
|
Houck, D.R. (2006) Preclinical Evaluation of SCY-635, a Cyclophilin Inhibitor with Potent Anti-HCV Activity. Hepatology, 44, S534.
|
[6]
|
Farci, P. and Purcell, R.H. (2000) Clinical Significance of Hepatitis C Virus Genotypes and Quasispecies. Seminars in Liver Disease, 20, 10-126.
|
[7]
|
Bedossa, P. and Poynard, T. (1996) An Algorithm for the Grading of Activity in Chronic Hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24, 289-293. http://dx.doi.org/10.1002/hep.510240201
|
[8]
|
Kaplan, M.M. and Bonis, P.A. (2009) Histologic Scoring Systems for Chronic Liver Disease.
|
[9]
|
Pohjanpelto, P., Lappalainen, M., Widell, A., Asikainen, K. and Paunio, M. (1996) Hepatitis C Genotypes in Finland Determined by RFLP. Clinical and Diagnostic Virology, 7, 7-16. http://dx.doi.org/10.1016/S0928-0197(96)00242-5
|
[10]
|
Simmonds, P. (2004) Genetic Diversity and Evolution of Hepatitis C Virus—15 Years on. Journal of General Virology, 85, 3173-3188. http://dx.doi.org/10.1099/vir.0.80401-0
|
[11]
|
Levrero, M. (2003) Cellular Mechanisms of Resistance to INFS. In: Ferenci, P., Ed., EASL Postgraduate Course, Istanbul, Turkey, Kenes International, Geneva.
|
[12]
|
Alsaran, K., Sabry, A. and Shaheen, N. (2011) Pegylated Interferon Alpha-2a for Treatment of Chronic HCV Infection in Hemodialysis Patients: A Single Saudi Center Experience. International Urology and Nephrology, 43, 865-873. http://dx.doi.org/10.1007/s11255-010-9756-1
|
[13]
|
Balan, V., Schwartz, D., Wu, G.Y., Muir, A.J., Ghalib, R., Jackson, J., Keeffe, E.B., Rossaro, L., Burnett, A., Goon, B.L., Bowers, P.J. and Leitz, G.J. (2005) Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin Erythropoietic Response to IFN/RBV Therapy. The American Journal of Gastroenterology, 100, 299-307. http://dx.doi.org/10.1111/j.1572-0241.2005.40757.x
|
[14]
|
Lavanchy, D. (2011) Evolving Epidemiology of Hepa-titis C Virus. Clinical Microbiology and Infection, 17, 107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x
|
[15]
|
Saleh, O., Baiomy, A.A., El-Desouky, A., Zaghloul, H., El-Arman, M., Dahab, G.M. and Abdel-Rahman, M.S. (2013) Hepatitis C Virus Genotype Distribution in Egyptian Diabetic Patients: A Preliminary Study. Arab Journal of Gastroenterology, 14, 14-19. http://dx.doi.org/10.1016/j.ajg.2013.01.005
|
[16]
|
Abravanel, F.L., Sauné1, K.S., Barange, K., Alric, L., Moreau, J., Desmorat, P., Vinel, J.P. and Izopet, J. (2004) Hepatitis C Virus Genotype 5: Epidemiological Characteristics and Sensitivity to Combination Therapy with Interferon-α Plus Ribavirin. The Journal of Infectious Diseases, 189, 1397-1400. http://dx.doi.org/10.1086/382544
|
[17]
|
Hui, C.K., Yuen, M.F., Sablon, E., Chan, A.O., Wong, B.C. and Lai, C.L. (2003) Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1. The Journal of Infectious Diseases, 187, 1071-1074. http://dx.doi.org/10.1086/368217
|
[18]
|
Chevaliez, S. (2013) New Markers for Diagnosis and Management of Chronic Hepatitis C Virus Infection. Annals of Gastroenterology, 26, 98-99.
|
[19]
|
DeLeuw, P., Sarraz, C. and Zeuzem, S. (2011) How to Use Virological Tools for the Optimal Management of Chronic Hepatitis C. Liver International, 31, 3-12. http://dx.doi.org/10.1111/j.1478-3231.2010.02398.x
|
[20]
|
Hamidi, F.M., Samarbaf, Z.A., Makvandi, M. and Hajiani, E. (2009) Determination of HCV Genotypes among Chronic Hepatic Patients in Ahvaz. Iranian Journal of Virology, 3, 12-16.
|
[21]
|
Pockros, P.J., Hamze, F.M., Martin, P., Lentz, E., Zhou, X., Govindarajan, S. and Lok, A.S. (2010) Histologic Outcomes in Hepatitis C—Infected Patients with Varying Degrees of Virologic Response to Interferon-Based Treatments. Hepatology, 52, 1193-1200. http://dx.doi.org/10.1002/hep.23809
|
[22]
|
Jármay, K., Lonovics, J. and Schaff, Z. (2003) Clinicopathologic Observations on Chronic Hepatitis C Therapy with Interferon-Alpha. Orvosi Hetilap, 144, 1325-1330.
|
[23]
|
Nachnani, J.S., Gidwani, R., Sadeddin, E., Clarkston, W.K., Fiorella, R. and Alba, L.M. (2007) Clinical Pathological Predictors to Predict Sustained Viral Response Rates in Patients with Chronic Hepatitis C Infection. Indian Journal of Gastroenterology, 26, 279-282.
|
[24]
|
Hung, C.H., Lee, C.M., Lu, S.N., Wang, J.H., Chen, C.H., Hu, T.H., Kee, K.M., Chang, K.C., Tseng, P.L., Yen, Y.H. and Changchien, C.S. (2006) Anemia Associated with Antiviral Therapy in Chronic Hepatitis C: Incidence, Risk Factors, and Impact on Treatment Response. Liver International, 26, 1079-1086. http://dx.doi.org/10.1111/j.1478-3231.2006.01354.x
|
[25]
|
Zeuzem, S., Feinman, S.V., Rasenack, J., et al. (2000) Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. The New England Journal of Medicine, 343, 1666-1672. http://dx.doi.org/10.1056/NEJM200012073432301
|
[26]
|
Kau, A., Vermehren, J. and Sarrazin, C. (2008) Treatment Predictors of a Sustained Virologic Response in Hepatitis B and C. Journal of Hepatology, 49, 634-651. http://dx.doi.org/10.1016/j.jhep.2008.07.013
|